

World Journal of *Gastroenterology*

World J Gastroenterol 2021 November 28; 27(44): 7582-7738



FRONTIER

- 7582** Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions
Couvineau A, Voisin T, Nicole P, Gratio V, Blais A

OPINION REVIEW

- 7597** Endoscopic management of difficult common bile duct stones: Where are we now? A comprehensive review
Tringali A, Costa D, Fugazza A, Colombo M, Khalaf K, Repici A, Anderloni A

EVIDENCE REVIEW

- 7612** Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions
Khan F, Tripathi D

REVIEW

- 7625** COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future
Anjum MR, Chalmers J, Hamid R, Rajoriya N

MINIREVIEWS

- 7649** Challenges in the diagnosis of intestinal neuronal dysplasia type B: A look beyond the number of ganglion cells
Terra SA, Gonçalves AC, Lourenção PLTA, Rodrigues MAM
- 7661** Treatment of *Helicobacter pylori* infection in the presence of penicillin allergy
Dutta AK, Phull PS

ORIGINAL ARTICLE

Basic Study

- 7669** Calycosin attenuates severe acute pancreatitis-associated acute lung injury by curtailing high mobility group box 1 - induced inflammation
Zhu CJ, Yang WG, Li DJ, Song YD, Chen SY, Wang QF, Liu YN, Zhang Y, Cheng B, Wu ZW, Cui ZC
- 7687** Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach
Jang HJ, Lee A, Kang J, Song IH, Lee SH

Observational Study

- 7705** Autosomal recessive 333 base pair interleukin 10 receptor alpha subunit deletion in very early-onset inflammatory bowel disease

Ly JJ, Su W, Chen XY, Yu Y, Xu X, Xu CD, Deng X, Huang JB, Wang XQ, Xiao Y

SYSTEMATIC REVIEWS

- 7716** Proton pump inhibitors and colorectal cancer: A systematic review

Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J

LETTER TO THE EDITOR

- 7734** SARS-CoV-2 infection in liver transplant recipients: A complex relationship

Alberca RW, Benard G, Alberca GGF, Sato MN

ABOUT COVER

Associate Editor of *World Journal of Gastroenterology*, Maria Gazouli, PhD, Professor, Basic Medical Sciences, Athens Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
mgazouli@med.uoa.gr

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Jia-Hui Li; Production Department Director: Yu-Jie Ma; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

November 28, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



SARS-CoV-2 infection in liver transplant recipients: A complex relationship

Ricardo Wesley Alberca, Gil Benard, Gabriela Gama Freire Alberca, Maria Notomi Sato

ORCID number: Ricardo Wesley Alberca 0000-0002-3602-3306; Gil Benard 0000-0002-5469-3602; Gabriela Gama Freire Alberca 0000-0002-3467-5562; Maria Notomi Sato 0000-0002-7911-1824.

Author contributions: All authors contributed to the conception, writing, and review of the article and approved the submitted version.

Conflict-of-interest statement: The authors declare having no conflicts of interest.

Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), No. 19/02679-7 and No. 20/13148-0.

Country/Territory of origin: Brazil

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Open-Access: This article is an open-access article that was

Ricardo Wesley Alberca, Laboratório de Dermatologia e Imunodeficiências (LIM-56), Departamento de Dermatologia e Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo 01246-903, Brazil

Gil Benard, Gabriela Gama Freire Alberca, Maria Notomi Sato, Laboratório de Dermatologia e Imunodeficiências (LIM-56), Departamento de Dermatologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo 01246-903, Brazil

Corresponding author: Ricardo Wesley Alberca, PhD, Academic Research, Research Fellow, Laboratório de Dermatologia e Imunodeficiências (LIM-56), Departamento de Dermatologia e Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de São Paulo, 455-Cerqueira César, São Paulo 01246-903, Brazil. ricardowesley@gmail.com

Abstract

The recent manuscript reviewed investigations involving liver damage in coronavirus disease 2019 (COVID-19) patients, and COVID-19 in patients with previous chronic hepatological diseases, such as patients with liver graft. The literature presents several conflicting results concerning the anti-SARS-CoV-2 response in patients with solid organ transplants, in liver transplant recipients. Therefore, we would like to humbly state a few points for consideration involving liver transplant recipients and COVID-19, such as the time since transplantation, comorbidities, and immunosuppressive regimens.

Key Words: COVID-19; SARS-CoV-2; Liver transplant; Immunosuppression; Infection; Comorbidities

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: There is not a consensus whether solid organ transplant recipients present increased severity or death rates due to coronavirus disease 2019 (COVID-19) compared with the general population. In particular, liver allograft has a low risk of rejection, therefore enabling treatment with relatively less immunosuppressive regimens. The reduction in the production of proinflammatory cytokines, without a drastic suppression of the immune response, may benefit liver transplant recipients during COVID-19. Further investigations should compare different organ transplant

selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Received: July 20, 2021

Peer-review started: July 20, 2021

First decision: August 6, 2021

Revised: August 14, 2021

Accepted: November 17, 2021

Article in press: November 17, 2021

Published online: November 28, 2021

P-Reviewer: Han J

S-Editor: Fan JR

L-Editor: A

P-Editor: Fan JR



recipients, elapsed time from the organ transplant, different immunosuppressive treatments, and their anti-SARS-CoV-2 response.

Citation: Alberca RW, Benard G, Alberca GGF, Sato MN. SARS-CoV-2 infection in liver transplant recipients: A complex relationship. *World J Gastroenterol* 2021; 27(44): 7734-7738

URL: <https://www.wjgnet.com/1007-9327/full/v27/i44/7734.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i44.7734>

TO THE EDITOR

We read with great interest the article entitled “Liver dysfunction and SARS-CoV-2 infection”, recently published by Gracia-Ramos *et al*[1] in the World Journal Gastroenterology[1]. Gracia-Ramos *et al*[1] performed a review on patients with liver dysfunction and coronavirus disease 2019 (COVID-19), highlighting investigations involving liver injury in COVID-19 patients, and COVID-19 in patients with previous chronic liver disease, such as cirrhosis and liver transplant recipients. Nevertheless, we would like to raise a few considerations regarding liver transplant recipients and COVID-19.

Transplantation is a treatment for organ failure and end-stage organ illnesses, requiring patients to undergo regular use of immunosuppressive treatment to avoid organ rejection[2]. There is no consensus regarding the increase in the incidence or severity of COVID-19 on solid organ transplant (SOT) recipients[3]. A few reports have identified an increase in severe COVID-19 and mortality rate in SOT recipients[4, 5], while others failed to do so[3, 6].

SOT patients may respond differently to COVID-19 due to associated comorbidities, the organ grafted, elapsed time from the transplant surgery, drugs used to prevent organ rejection, or drugs used to treat SARS-CoV-2 infection[7-9]. The identification of the organ grafted is usually described in the manuscripts[6], but only one manuscript with comparison between the different organ transplant recipients has been made so far, identifying an increase in mortality in kidney and heart transplant recipients in comparison to liver transplant recipients[5].

A systematic review identified a similar death rate in liver transplant recipients and non-transplant recipients, but a higher percentage of non-transplant recipients were obese or had cardiovascular or respiratory diseases[10]. Hospitalization in the intensive care unit presented mixed results, and only one investigation reported the need for mechanical ventilation, and liver transplant recipients presented a greater need for it, in comparison to non-SOT patients[10]. Consequently, it is not possible to confirm if liver transplant recipients have a lower risk for severe illness or death risk in comparison to non-transplant recipients during COVID-19.

The liver allograft has a lower risk of rejection in comparison to heart and kidney allograft. Therefore, it is usually treated with reduced immunosuppressive regimens compared with the other SOT patients[11, 12]. Different immunosuppressive regimens can affect the detection of SARS-CoV-2 RNA in nasopharyngeal swab tests[13]. Tacrolimus, a commonly used drug by SOT patients, has been shown to display anti-coronavirus effects in vitro[14] and putative protective properties in liver transplant recipients with COVID-19[15]. In contrast, another report identified that tacrolimus has no significant effect on the mortality risk[16].

We hypothesize that the inhibition of the calcineurin by tacrolimus could curb the production of proinflammatory cytokines, similarly to the observed in other inflammatory models[17-19], and reduce or prevent the development of the cytokine storm in COVID-19[20]. A recent report associated tacrolimus therapy with a protective effect in liver transplant recipients with COVID-19[15]. Importantly, the use of tacrolimus in association with dexamethasone in immunocompetent COVID-19 patients is currently being tested in a Spanish clinical trial (clinicaltrials.gov/ct2/show/NCT04341038).

Importantly, SOT recipients (including liver, kidney, heart, lung, and others) have an increased risk of mortality due to infections in the first year after the transplant[21], especially respiratory infections[22]. A recent review identified a higher mortality rate in patients with over a year of organ graft[23]. Another report identified no difference in elapsed time from transplant in survival and non-survival COVID-19 patients, but

patients presented a high incidence of other comorbidities[24]. In a recent report, liver transplant was not associated with greater mortality risk, while the association with other comorbidities (mainly diabetes, hypertension, obesity, and cardiovascular disease) posed a higher death risk[25]. It is reasonable to assume that comorbidities associated with poor outcomes in non-SOT patients will also influence the COVID-19 disease course in liver recipients, such as co-infection[26], respiratory disorders[27], and alcohol consumption[28]. In another report, liver transplant recipients presented similar mortality to non-SOT patients and reduced mortality in comparison with patients with liver cirrhosis[29].

On the other hand, liver transplant recipients developed lower levels of anti-SARS-CoV-2 IgG, and a more pronounced reduction in SARS-CoV-2-specific IgG levels, 6 mo after COVID-19[30]. Therefore, a long-term follow-up is necessary to fully determine the duration of the anti-SARS-CoV-2 immune response and the long-term protection offered by COVID-19 vaccines in liver transplant recipients. A recent report has identified SARS-CoV-2 infections in fully vaccinated SOT patients, and, importantly, the death of a fully vaccinated heart transplant patient due to COVID-19[30].

In conclusion, Gracia-Ramos *et al*[1] presented interesting points concerning liver transplant recipients with COVID-19. However, further investigations are needed to better understand the impact of comorbidities, elapsed time since the organ transplant, immunosuppressive regimen, and vaccination on COVID-19 in liver transplant patients.

REFERENCES

- 1 **Gracia-Ramos AE**, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. *World J Gastroenterol* 2021; **27**: 3951-3970 [PMID: [34326607](#) DOI: [10.3748/wjg.v27.i26.3951](#)]
- 2 **Zhang H**, Dai H, Xie X. Solid Organ Transplantation During the COVID-19 Pandemic. *Front Immunol* 2020; **11**: 1392 [PMID: [32612614](#) DOI: [10.3389/fimmu.2020.01392](#)]
- 3 **Ringer M**, Azmy V, Kaman K, Tang D, Cheung H, Azar MM, Price C, Malinis M. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients. *Transpl Infect Dis* 2021; **23**: e13556 [PMID: [33378571](#) DOI: [10.1111/tid.13556](#)]
- 4 **Elias M**, Pievani D, Randoux C, Louis K, Denis B, Delion A, Le Goff O, Antoine C, Greze C, Pillebout E, Abboud I, Glotz D, Daugas E, Lefaucheur C. COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. *J Am Soc Nephrol* 2020; **31**: 2413-2423 [PMID: [32847984](#) DOI: [10.1681/ASN.2020050639](#)]
- 5 **Alberca RW**, Alberca GGF, Netto LC, Orfali RL, Gozzi-Silva SC, Duarte AJ da S, Aoki V, Sato MN, Benard G. COVID-19 Severity and Mortality in Solid Organ Transplantation: Differences between Liver, Heart, and Kidney Recipients. *Transplantation* 2021; **2**: 296-303 [DOI: [10.3390/transplantation2030030](#)]
- 6 **Pereira MR**, Arcasoy S, Farr MA, Mohan S, Emond JC, Tsapepas DS, Shi Q, Purpura L, Uhlemann AC, Zucker J, Verna EC. Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study. *Transpl Infect Dis* 2021; **23**: e13637 [PMID: [33993630](#) DOI: [10.1111/tid.13637](#)]
- 7 **Nacif LS**, Zanini LY, Waisberg DR, Pinheiro RS, Galvão F, Andraus W, D'Albuquerque LC. COVID-19 in solid organ transplantation patients: A systematic review. *Clinics (Sao Paulo)* 2020; **75**: e1983 [PMID: [32520225](#) DOI: [10.6061/clinics/2020/e1983](#)]
- 8 **Hage R**, Steinack C, Gautschi F, Pfister S, Inci I, Schuurmans MM. Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19. *Transplantation* 2021; **2**: 229-45 [DOI: [10.3390/transplantation2020022](#)]
- 9 **Kulkarni AV**, Tevethia HV, Premkumar M, Arab JP, Candia R, Kumar K, Kumar P, Sharma M, Rao PN, Reddy DN. Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis. *EClinicalMedicine* 2021; **38**: 101025 [PMID: [34278287](#) DOI: [10.1016/j.eclinm.2021.101025](#)]
- 10 **Eason JD**, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? *Transplantation* 2005; **79**: 1157-1159 [PMID: [15880061](#) DOI: [10.1097/01.tp.0000162084.46555.10](#)]
- 11 **Beimler J**, Morath C, Zeier M. [Modern immunosuppression after solid organ transplantation]. *Internist (Berl)* 2014; **55**: 212-222 [PMID: [24518922](#) DOI: [10.1007/s00108-013-3411-8](#)]
- 12 **Gaston DC**, Malinis M, Osborn R, Peaper DR, Landry M, Juthani-Mehta M, Azar MM. Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients. *Am J Transplant* 2021; **21**: 1304-1311 [PMID: [33043603](#) DOI: [10.1111/ajt.16357](#)]
- 13 **Carbajo-Lozoya J**, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. *Virus Res* 2012; **165**: 112-117 [PMID: [22349148](#) DOI: [10.1016/j.virusres.2012.02.002](#)]
- 14 **Belli LS**, Fondevila C, Cortesi PA, Conti S, Karam V, Adam R, Coilly A, Ericzon BG, Loinaz C, Cuervas-Mons V, Zambelli M, Llado L, Diaz-Fontenla F, Invernizzi F, Patrono D, Faitot F, Bhooori

- S, Pirenne J, Perricone G, Magini G, Castells L, Detry O, Cruchaga PM, Colmenero J, Berrevoet F, Rodriguez G, Ysebaert D, Radenne S, Metselaar H, Morelli C, De Carlis LG, Polak WG, Duvoux C; ELITA-ELTR COVID-19 Registry. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. *Gastroenterology* 2021; **160**: 1151-1163.e3 [PMID: [33307029](#) DOI: [10.1053/j.gastro.2020.11.045](#)]
- 15 **Dumortier J**, Duvoux C, Roux O, Altieri M, Barraud H, Besch C, Caillard S, Coilly A, Conti F, Dharancy S, Durand F, Francoz C, Garaix F, Housset-Debry P, Kounis I, Lassailly G, Laverdure N, Leroy V, Mallet M, Mazzola A, Meunier L, Radenne S, Richardet JP, Vanlemmens C, Hazzan M, Saliba F; French Solid Organ Transplant COVID Registry; Groupe de Recherche Français en Greffe de Foie (GReF²). Covid-19 in liver transplant recipients: the French SOT COVID registry. *Clin Res Hepatol Gastroenterol* 2021; **45**: 101639 [PMID: [33636654](#) DOI: [10.1016/j.clinre.2021.101639](#)]
- 16 **Yoshino T**, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, Ueno S, Uza N, Masuda S, Inui K, Chiba T. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. *Inflamm Bowel Dis* 2010; **16**: 2022-2033 [PMID: [20848491](#) DOI: [10.1002/ibd.21318](#)]
- 17 **Szabo G**, Gavalá C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. *J Invest Med* 2001; **49**: 442-449 [PMID: [11523700](#) DOI: [10.2310/6650.2001.33789](#)]
- 18 **Tsuda K**, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, Gabazza EC, Mizutani H. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells. *PLoS One* 2012; **7**: e31465 [PMID: [22359594](#) DOI: [10.1371/journal.pone.0031465](#)]
- 19 **Peter AE**, Sandeep BV, Rao BG, Kalpana VL. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. *Front Pharmacol* 2020; **11**: 583777 [PMID: [33708109](#) DOI: [10.3389/fphar.2020.583777](#)]
- 20 **Singh N**, Limaye AP. Infections in Solid-Organ Transplant Recipients [Internet]. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier Inc., 2014: 3440-3452
- 21 **Kumar D**, Michaels MG, Morris MI, Green M, Avery RK, Liu C, Danziger-Isakov L, Stosor V, Estabrook M, Gantt S, Marr KA, Martin S, Silveira FP, Razonable RR, Allen UD, Levi ME, Lyon GM, Bell LE, Huprikar S, Patel G, Gregg KS, Pursell K, Helmersen D, Julian KG, Shiley K, Bono B, Dharnidharka VR, Alavi G, Kalpoe JS, Shoham S, Reid GE, Humar A; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. *Lancet Infect Dis* 2010; **10**: 521-526 [PMID: [20620116](#) DOI: [10.1016/S1473-3099\(10\)70133-X](#)]
- 22 **Imam A**, Abukhalaf SA, Merhav H, Abu-Gazala S, Cohen-Arazi O, Pikarsky AJ, Safadi R, Khalaileh A. Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review. *Ann Transplant* 2020; **25**: e926196 [PMID: [33106469](#) DOI: [10.12659/AOT.926196](#)]
- 23 **Webb GJ**, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. *Lancet Gastroenterol Hepatol* 2020; **5**: 643-644 [PMID: [32339474](#) DOI: [10.1016/S2468-1253\(20\)30125-4](#)]
- 24 **Webb GJ**, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, Catana MA, Cargill T, Dhanasekaran R, García-Juárez I, Hagström H, Kennedy JM, Marshall A, Masson S, Mercer CJ, Perumalswami PV, Ruiz I, Thaker S, Ufere NN, Barnes E, Barritt AS 4th, Moon AM. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. *Lancet Gastroenterol Hepatol* 2020; **5**: 1008-1016 [PMID: [32866433](#) DOI: [10.1016/S2468-1253\(20\)30271-5](#)]
- 25 **Alberca RW**, Yendo TM, Leuzzi Ramos YÁ, Fernandes IG, Oliveira LM, Teixeira FME, Beserra DR, de Oliveira EA, Gozzi-Silva SC, Andrade MMS, Branco ACCC, Pietrobon AJ, Pereira NZ, de Brito CA, Orfali RL, Aoki V, Duarte AJDS, Benard G, Sato MN. Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients. *Am J Trop Med Hyg* 2020; **103**: 2353-2356 [PMID: [33025877](#) DOI: [10.4269/ajtmh.20-1185](#)]
- 26 **Alberca RW**, Lima JC, de Oliveira EA, Gozzi-Silva SC, Leuzzi YÁ, Mary De Souza Andrade M, Beserra DR, Oliveira LDM, Castelo Branco ACC, Pietrobon AJ, Pereira NZ, Teixeira FME, Fernandes IG, Benard G, Sato MN. COVID-19 disease course in formers smokers, smokers and COPD patients. *Front Physiol* 2020 [DOI: [10.3389/fphys.2020.637627](#)]
- 27 **Alberca RW**, Rigato PO, Ramos YÁL, Teixeira FME, Branco ACC, Fernandes IG, Pietrobon AJ, Duarte AJDS, Aoki V, Orfali RL, Sato MN. Clinical Characteristics and Survival Analysis in Frequent Alcohol Consumers With COVID-19. *Front Nutr* 2021; **8**: 689296 [PMID: [34150832](#) DOI: [10.3389/fnut.2021.689296](#)]
- 28 **Jayant K**, Reccia I, Virdis F, Pyda JS, Bachul PJ, di Sabato D, Barth RN, Fung J, Baker T, Witkowski P. COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis. *Clin Transplant* 2021; **35**: e14246 [PMID: [33555058](#) DOI: [10.1111/ctr.14246](#)]
- 29 **Caballero-Marcos A**, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Olmedo M, Graus Morales J, Cuervas-Mons V, Cachero A, Loinaz-Seguro C, Iñarraiaegui M, Castells L, Pascual S, Vinaixa-Aunés C, González-Grande R, Otero A, Tomé S, Tejedor-Tejada J, Álamo-Martínez JM, González-Diéguez L, Nogueras-Lopez F, Blanco-Fernández G, Muñoz-Bartolo G, Bustamante FJ, Fábrega E, Romero-Cristóbal M, Martín-Mateos R, Del Río-Izquierdo J, Arias-Milla A, Calatayud L, Marcacuzco-Quinto AA, Fernández-Alonso V, Gómez-Gavara C, Colmenero J, Muñoz P, Pons JA;

- Spanish Society of Liver Transplantation (SETH). Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. *Am J Transplant* 2021; **21**: 2876-2884 [PMID: [33835707](#) DOI: [10.1111/ajt.16599](#)]
- 30 Ali NM, Alnazari N, Mehta SA, Boyarsky B, Avery RK, Segev DL, Montgomery RA, Stewart ZA. Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. *Transplantation* 2021; **105**: e104-e106 [PMID: [34049360](#) DOI: [10.1097/TP.0000000000003836](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

